NO325722B1 - Salve innholdende acetylsalisylsyre - Google Patents
Salve innholdende acetylsalisylsyre Download PDFInfo
- Publication number
- NO325722B1 NO325722B1 NO19990878A NO990878A NO325722B1 NO 325722 B1 NO325722 B1 NO 325722B1 NO 19990878 A NO19990878 A NO 19990878A NO 990878 A NO990878 A NO 990878A NO 325722 B1 NO325722 B1 NO 325722B1
- Authority
- NO
- Norway
- Prior art keywords
- acetylsalicylic acid
- ointment
- ointments
- mixture
- ointment containing
- Prior art date
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims description 48
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims description 48
- 239000002674 ointment Substances 0.000 title claims description 40
- 239000004215 Carbon black (E152) Substances 0.000 claims description 8
- 229930195733 hydrocarbon Natural products 0.000 claims description 8
- 150000002430 hydrocarbons Chemical class 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 6
- 229940099259 vaseline Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 5
- 235000019271 petrolatum Nutrition 0.000 description 5
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000411 camphor oil Drugs 0.000 description 1
- 239000010624 camphor oil Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- -1 yellow vaseline Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16851397A JP4729149B2 (ja) | 1997-06-25 | 1997-06-25 | 安定なアスピリン軟膏製剤 |
| PCT/JP1998/002781 WO1998058652A1 (fr) | 1997-06-25 | 1998-06-23 | Preparations stables sous forme d'onguent a base d'aspirine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO990878D0 NO990878D0 (no) | 1999-02-24 |
| NO990878L NO990878L (no) | 1999-04-21 |
| NO325722B1 true NO325722B1 (no) | 2008-07-07 |
Family
ID=15869442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19990878A NO325722B1 (no) | 1997-06-25 | 1999-02-24 | Salve innholdende acetylsalisylsyre |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7029663B1 (fr) |
| EP (1) | EP0930070B1 (fr) |
| JP (1) | JP4729149B2 (fr) |
| KR (1) | KR100560892B1 (fr) |
| CN (1) | CN1216606C (fr) |
| AU (1) | AU714772B2 (fr) |
| CA (1) | CA2264028C (fr) |
| DE (1) | DE69811846T2 (fr) |
| DK (1) | DK0930070T3 (fr) |
| ES (1) | ES2193533T3 (fr) |
| HK (1) | HK1020014A1 (fr) |
| NO (1) | NO325722B1 (fr) |
| WO (1) | WO1998058652A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4791682B2 (ja) * | 2003-02-21 | 2011-10-12 | 帝國製薬株式会社 | 痔疾患用治療剤 |
| FR2854802B1 (fr) * | 2003-05-12 | 2005-06-24 | Galderma Res & Dev | Procede de preparation d'une formulation contenant un principe actif microdose |
| WO2011076401A1 (fr) * | 2009-12-23 | 2011-06-30 | Holger Schankin | Compositions pharmaceutiques sensiblement exemptes d'eau, contenant de l'acide acétylsalicylique |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB469526A (en) | 1936-10-02 | 1937-07-27 | Earl Barger Putt | Acetyl-salicylic acid composition |
| US4012508A (en) * | 1975-02-03 | 1977-03-15 | Burton Verna M | Topical composition and method |
| US4164563A (en) * | 1975-03-24 | 1979-08-14 | Minnesota Mining And Manufacturing Company | Non-greasy compositions |
| DE2755224A1 (de) * | 1976-12-15 | 1978-07-13 | Procter & Gamble | Schmerzen und entzuendungen linderndes mittel zur oertlichen anwendung |
| US4228162A (en) | 1979-07-09 | 1980-10-14 | Research Corporation | Dimethyl isosorbide in liquid formulation of aspirin |
| JPS59137408A (ja) * | 1983-01-27 | 1984-08-07 | Taisho Pharmaceut Co Ltd | 軟膏 |
| IL68965A (en) | 1983-06-13 | 1987-02-27 | Rafa Labor Ltd | Topical pharmaceutical preparation comprising acetylsalicylic acid for the treatment of dermatological disorders |
| US4613498A (en) * | 1984-10-24 | 1986-09-23 | Frank Crosby | Hemorrhoid medication |
| DK8603837A (fr) | 1985-08-13 | 1987-02-14 | ||
| JPS62267232A (ja) * | 1986-05-15 | 1987-11-19 | Shigehiro Arai | 汗疱状白癬治療用外用剤 |
| JP3040427B2 (ja) * | 1989-05-18 | 2000-05-15 | 帝國製薬株式会社 | 神経痛治療用アスピリン含有軟膏組成物 |
| JPH04346930A (ja) | 1991-05-25 | 1992-12-02 | Sumitomo Pharmaceut Co Ltd | 安定なアスピリン腸溶錠 |
| JP3273805B2 (ja) | 1992-03-04 | 2002-04-15 | ポーラ化成工業株式会社 | 消炎鎮痛外用剤 |
| JP3554573B2 (ja) | 1992-06-30 | 2004-08-18 | 積水化学工業株式会社 | アスピリン含有経皮吸収製剤 |
| JPH06183980A (ja) | 1992-12-24 | 1994-07-05 | Sekisui Chem Co Ltd | アスピリン含有貼付剤の製造方法 |
| JPH08113531A (ja) | 1994-10-14 | 1996-05-07 | Sekisui Chem Co Ltd | 医療用貼付剤 |
| JPH08208487A (ja) * | 1995-02-01 | 1996-08-13 | Sekisui Chem Co Ltd | 炎症性皮膚疾患治療用外用剤 |
| DE69635298T2 (de) * | 1995-12-26 | 2006-07-13 | Teikoku Seiyaku K.K. | Verwendung von Acetylsalicylsäuren zur Herstellung eines Medikaments für die Behandlung von Hautverletzungen |
| JP3979689B2 (ja) | 1995-12-26 | 2007-09-19 | 帝國製薬株式会社 | アセチルサリチル酸含有皮膚損傷治療剤 |
-
1997
- 1997-06-25 JP JP16851397A patent/JP4729149B2/ja not_active Expired - Fee Related
-
1998
- 1998-06-23 CA CA002264028A patent/CA2264028C/fr not_active Expired - Fee Related
- 1998-06-23 DE DE69811846T patent/DE69811846T2/de not_active Expired - Lifetime
- 1998-06-23 WO PCT/JP1998/002781 patent/WO1998058652A1/fr active IP Right Grant
- 1998-06-23 EP EP98928621A patent/EP0930070B1/fr not_active Expired - Lifetime
- 1998-06-23 ES ES98928621T patent/ES2193533T3/es not_active Expired - Lifetime
- 1998-06-23 DK DK98928621T patent/DK0930070T3/da active
- 1998-06-23 AU AU80384/98A patent/AU714772B2/en not_active Ceased
- 1998-06-23 KR KR1019997001469A patent/KR100560892B1/ko not_active IP Right Cessation
- 1998-06-23 US US09/242,700 patent/US7029663B1/en not_active Expired - Lifetime
- 1998-06-23 CN CN988011751A patent/CN1216606C/zh not_active Expired - Fee Related
-
1999
- 1999-02-24 NO NO19990878A patent/NO325722B1/no not_active IP Right Cessation
- 1999-11-16 HK HK99105279A patent/HK1020014A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DK0930070T3 (da) | 2003-05-05 |
| NO990878D0 (no) | 1999-02-24 |
| CA2264028A1 (fr) | 1998-12-30 |
| ES2193533T3 (es) | 2003-11-01 |
| JP4729149B2 (ja) | 2011-07-20 |
| KR20000068312A (ko) | 2000-11-25 |
| AU714772B2 (en) | 2000-01-13 |
| CA2264028C (fr) | 2009-01-27 |
| EP0930070B1 (fr) | 2003-03-05 |
| DE69811846D1 (de) | 2003-04-10 |
| CN1216606C (zh) | 2005-08-31 |
| EP0930070A4 (fr) | 2000-01-26 |
| US7029663B1 (en) | 2006-04-18 |
| HK1020014A1 (en) | 2000-03-10 |
| CN1236317A (zh) | 1999-11-24 |
| AU8038498A (en) | 1999-01-04 |
| EP0930070A1 (fr) | 1999-07-21 |
| KR100560892B1 (ko) | 2006-03-13 |
| JPH1112176A (ja) | 1999-01-19 |
| DE69811846T2 (de) | 2003-11-13 |
| NO990878L (no) | 1999-04-21 |
| WO1998058652A1 (fr) | 1998-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5544544B2 (ja) | 塩基性薬効成分の脂肪酸塩、安息香酸塩を含有する外用剤とその製造方法 | |
| CN1081030C (zh) | 含有曲尼司特的外用制剂及其制备方法 | |
| Dubach et al. | Enzymatic activity of the isolated glomerulus in normal and nephrotic rats | |
| Hemmati et al. | Anti-atherogenic potential of natural honey: anti-diabetic and antioxidant approaches | |
| WO1998016212A1 (fr) | Anesthesique local a usage externe | |
| Kim et al. | Effects of tegoprazan, a novel potassium-competitive acid blocker, on rat models of gastric acid–related disease | |
| Basu et al. | Preparation and characterisation of mucoadhesive nasal gel of venlafaxine hydrochloride for treatment of anxiety disorders | |
| NO325722B1 (no) | Salve innholdende acetylsalisylsyre | |
| Crowe et al. | An Experimental Model of Analgesic-Induced Renal Damage—Some Effects of ρ-Aminophenol on Rat Kidney Mitochondria | |
| Rao et al. | Platelet aggregation independent of ADP release or prostaglandin synthesis in patients with Hermansky-Pudlak syndrome | |
| US5240917A (en) | Suppression of thromboxane levels by percutaneous administration of aspirin | |
| CA1207667A (fr) | Onguent contenant du propionate butyrate d'hydrocortisone | |
| DK167735B1 (da) | Fast praeparat indeholdende et aluminiumsalt af en saccharosesulfatester og polyethylenglycol, samt fremgangsmaade til fremstilling af praeparatet | |
| Ali et al. | Honey potentiates the gastric protection effects of sucralfate against ammonia-induced gastric lesions in rats | |
| EP0714240B1 (fr) | Absorption reduite d'acides gras | |
| Ezzedeen et al. | Release of sorbic acid from ointment bases | |
| Gupta et al. | Effect of other drugs and chemicals on the degradation of aspirin in vitro: possible extrapolation to in vivo metabolism of aspirin | |
| HUE028045T2 (en) | Intravenous ibuprofen infusion | |
| RU2705794C1 (ru) | Комбинированная мягкая лекарственная форма для лечения геморроидальных заболеваний | |
| RU1803100C (ru) | Состав дл мазевой основы | |
| Boeijinga et al. | Double blind study of the effect of glafenine (Glifanan®) on oral anticoagulant therapy with phenprocoumon (Marcumar®) | |
| Olaniyi et al. | Gastroprotective mechanisms of Entandrophragma angolense extract against indomethacin-induced gastric ulceration in rats | |
| KR910005703B1 (ko) | 베타-콜린산 유도체가 포함된 의약조성물 | |
| Jabarah et al. | Salicylate intoxication from topically applied salicylic acid | |
| RU2185150C2 (ru) | Мазь димексида, приготовленная на геле полиэтиленоксида 1500, обладающая противовоспалительным действием |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |